Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

of Plicera pending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

As previously reported, the Company suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 for the treatment of Pompe Disease and received notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold.

The Company continues to work closely with the FDA to determine appropriate next steps for advancing the development of AT2220 and expects to provide guidance on this progress over the upcoming months.

Additionally, Amicus continues to be encouraged with its preclinical studies with AT2220 in combination with ERT. As previously announced, the Company expects to report additional data from these activities throughout the remainder of 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research to assess the potential for applying its versatile chaperone technology platform to the treatment of a broad range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

Appointment of New Director

The Company announced today the election of James Barrett, Ph.D., to its Board of Directors. Dr. Barrett currently serves as General Partner of New Enterprise Associates (NEA), the Company's single largest shareholder, where he specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Prior to joining NEA in 2001, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... June 28, 2011 While the health benefits of oregano ... organic Oregano Oil blend from Global Healing Center is one ... market, which is exactly why it,s gaining popularity as a ... contains a minimum of 80% Carvacrol, a compound that is ...
... LA JOLLA, Calif., June 27, 2011 Celladon Corp., ... of innovative treatments for cardiovascular diseases, announces that the ... of MYDICAR® for the treatment of advanced heart failure ... Heart Association journal. "I am very ...
... Pa., June 27, 2011 Morphotek®, Inc., a subsidiary of ... campaign to collect 8,792 pounds of food from its employees, ... year. With approximately 200 employees at Morphotek, this number equates ... food will be donated to local needy families through collaboration ...
Cached Biology Technology:Organic Oregano Oil Gaining Popularity in Natural Health Field, According to Global Healing Center 2Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation 2Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation 3Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation 4Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 2Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 3
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... of Ascension Island, one of the world,s largest green ... Writing in the journal Biodiversity and Conservation , ... Government Conservation Department report that the number of green ... increased by more than 500 per cent since records ... are now estimated to be laid on the Island,s ...
(Date:7/29/2014)... of Kent has shown for the first time how ... that could have a major impact on cancer therapy ... uncovered the mechanism whereby the physical properties of the ... are ,fine-tuned, to undertake different functions. , While ... providing a framework for the cell, others are more ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... AKRON, Ohio, June 16, 2011 Leaders within the ... to apply "Value-driven Engineering" (VdE) to enhance the development ... efficiency and reduced complexity.  VdE will become a key ... economy," maintain global competitiveness, and assure access to device ...
... Robert Blelloch, MD, PhD, has received the 2011 Outstanding Young ... for his pioneering research on the role of molecular tools ... Blelloch will present his research today, June 15, 2011, at ... p.m. EDT). He will participate in a press briefing at ...
... new Baylor University study has found that sunlight decreases the ... the southern United States every year. While golden algae ... Texas rivers and lakes, including Lake Whitney and Lake Waco ... believe that several environmental factors influence toxin production, but new ...
Cached Biology News:U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 2U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 3U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 4UCSF stem cell, cancer scientist honored for pioneering studies 2UCSF stem cell, cancer scientist honored for pioneering studies 3
... Flat bottoms,• Nonreversible ... to reduce contamination,• Individual ... identification,• Uniform footprint for ... for optimal cell attachment,• ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: